Author: Bays, Harold E

Source: Expert Review of Cardiovascular Therapy, Volume 2, Number 4, July 2004 , pp. 485-501(17)

Publisher: Expert Reviews

Abstract:

Many clinical studies have demonstrated that lipid-altering drug treatments, including the use of statin and niacin monotherapy, can be effective in the primary and secondary prevention of coronary heart disease, but only in a minority of patients relative to placebo. Since statins and niacin have entirely different mechanisms of action and predominantly different effects on blood lipid levels, the combined use of both a statin and niacin may confer complementary benefits on multiple lipid parameters, produce a more global improvement in lipid blood levels and result in greater reductions in coronary heart disease risk factors than the administration of either agent alone. This may be of particular importance in patients with complex dyslipidemias, such as those with Type 2 diabetes mellitus and metabolic syndrome. This review summarizes the efficacy and safety of extended-release niacin/lovastatin (Advicor^®, Kos Pharmaceuticals Inc.), the first combination product approved for the management of dyslipidemia.

Keywords: coronary heart disease; diabetes mellitus; extended-release niacin; HDL-cholesterol; LDL-cholesterol; lipoprotein(a); lovastatin; metabolic syndrome; niacin; statin; triglyceride

Document Type: Drug Evaluation

DOI: http://dx.doi.org/10.1586/14779072.2.4.485

Publication date: 2004-07-01

More about this publication?

• Expert Review of Cardiovascular Therapy provides expert commentary on the clinical applications of the new medicines, therapeutic agents and diagnostics in cardiovascular disease. Coverage inculdes drug therapy, heart disease, vascular disorders, hypertension, cholesterol in cardiovascular disease, heart disease, stroke, heart failure and cardiovascular surgery.
• Editorial Board
• Information for Authors
• Submit a Paper
• Subscribe to this Title
• Information for Advertisers
• Terms & Conditions
• Information for Librarians
• Free Trials
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Cardiovascular Medicine ,  Pharmacology
• By this author: Bays, Harold E

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers